Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805394 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2HPGDNPC1HSD11B1 | |
| SCHEMBL905280 | 0.91 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2HPGDHSD11B1USP2 | |
| SCHEMBL905275 | 0.91 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2HPGDHSD11B1USP2 | |
| SCHEMBL16369976 | 0.91 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2HPGDHSD11B1USP2 | |
| SCHEMBL17964198 | 0.90 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2HPGDNPC1HSD11B1 | |
| SCHEMBL21408159 | 0.81 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2HPGDNPC1HSD11B1 | |
| SCHEMBL27207278 | 0.81 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2HPGDUSP2 | |
| SCHEMBL27203890 | 0.81 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2HPGDUSP2 | |
| SCHEMBL9192788 | 0.80 | RAB9A (0.39) | ALDH1A1 | |
| SCHEMBL7456496 | 0.79 | DPP4 (0.38) | HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695236-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024216094-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-01-31 | — | — | US | disclosed |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2021124172-A1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, ZFX, HBG1 | HSD17B10 1799/4885SMN1; SMN2 132/4885HPGD 1581/4885 |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HSD17B10 2991/4885SMN1; SMN2 4787/4885HPGD 1773/4885 |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, ZFX, HBG1 | HSD17B10 1867/4885SMN1; SMN2 138/4885HPGD 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.